Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK China Investigation Outcome
GlaxoSmithKline plc (GSK) announced that China ruled that GSK China Investment Co. Ltd has, according to Chinese law been found guilty
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa
GSK announced a £5m collaboration with UK and SAMRC, to support much-needed research into NCDs in Africa, part of GSK Open Lab initiative.
GSK, GOLD and the COPD Foundation announce formation of a new external expert Governance Board for the COPD Assessment Test (CAT)
At the ERS International Congress in Germany, GSK, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) ...
GSK announces first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study
GSK announced, phase IIIb/IV study to investigate combination therapy of ambrisentan and tadalafil in treatment naïve patients...
New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma
NEJM presented at ERS data from Phase III asthma studies of mepolizumab, an investigational IL-5 antagonist monoclonal antibody.
GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions
GSK presented data at ERS Congress showing blood eosinophil levels may help predict patients with COPD when receiving an ICS regimen.
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
ViiV announced, the EC has granted marketing authorisation for Triumeq® for the treatment of HIV in those aged 12+ and weighing 40kg+.
Ebola vaccine trials fast-tracked by international consortium
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine
GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication
New first-in-class treatment option for this previously treated SAA patient population
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
ViiV announced that the FDA has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg), treatment of HIV-1 infection.
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma
GSK announced that the FDA has approved Arnuity™ Ellipta® for treatment of asthma in patients aged 12 years and older.
GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL
GSK & GEN announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a phase III study, PROLONG (OMB 112517)
GSK announces EU regulatory submission for malaria vaccine candidate RTS,S
GSK announced today that it has submitted a regulatory application to the EMA for its malaria vaccine candidate, RTS,S.
FDA approves Flonase allergy relief for sale over-the-counter in the United States
No. 1 prescribed allergy treatment ingredient1 to be available OTC
Results announcement for the second quarter 2014
GSK delivers Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis (both CER). Q2 dividend 19p (+6%).
ViiV Healthcare presents phase III data
An investigational two drug-regimen of maraviroc with DRV/r showed inferior efficacy compared to emtricitabine/tenofovir with DRV/r.
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early
GSK announced that the IDMC recommended COMBI-v phase III study of Mekinist™, in combination with Tafinlar™ be stopped early.
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
GSK and Theravance, Inc. today announced the start of a global phase III study, known as IMPACT.
GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation
GSK announced, the EC has granted marketing authorisation for trametinib as treatment of patients with unresectable/metastatic melanoma
Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD
GSK & THRX announced that JMHLW has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms with COPD